CN102399752A - 心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 - Google Patents
心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 Download PDFInfo
- Publication number
- CN102399752A CN102399752A CN2011103361900A CN201110336190A CN102399752A CN 102399752 A CN102399752 A CN 102399752A CN 2011103361900 A CN2011103361900 A CN 2011103361900A CN 201110336190 A CN201110336190 A CN 201110336190A CN 102399752 A CN102399752 A CN 102399752A
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- monoclonal antibody
- binding protein
- mcf1
- acid binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 title claims abstract description 12
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 title claims abstract description 12
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 33
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 101100221226 Zea mays COAC2 gene Proteins 0.000 claims abstract description 22
- 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 claims abstract description 13
- 102000047025 human FABP3 Human genes 0.000 claims abstract description 13
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 230000003248 secreting effect Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 25
- 238000002965 ELISA Methods 0.000 claims description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 10
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims description 8
- 108091022862 fatty acid binding Proteins 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000002331 protein detection Methods 0.000 claims description 4
- 238000003118 sandwich ELISA Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims 1
- 238000003908 quality control method Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 2
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 79
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 79
- 238000006243 chemical reaction Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 101000615238 Homo sapiens Proto-oncogene DBL Proteins 0.000 description 13
- 102100021384 Proto-oncogene DBL Human genes 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000001641 gel filtration chromatography Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000024835 cytogamy Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 amino glycocoll Chemical compound 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 102100026748 Fatty acid-binding protein, intestinal Human genes 0.000 description 1
- 108050008832 Fatty acid-binding protein, intestinal Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034647 Peristalsis visible Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920004935 Trevira® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000037892 acute myocardial injury Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000022534 visible peristalsis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110336190A CN102399752B (zh) | 2011-10-28 | 2011-10-28 | 心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110336190A CN102399752B (zh) | 2011-10-28 | 2011-10-28 | 心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102399752A true CN102399752A (zh) | 2012-04-04 |
CN102399752B CN102399752B (zh) | 2012-10-24 |
Family
ID=45882404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110336190A Expired - Fee Related CN102399752B (zh) | 2011-10-28 | 2011-10-28 | 心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102399752B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102735849A (zh) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | 一种人心肌脂肪酸结合蛋白酶促化学发光免疫检测方法和试剂盒 |
CN103045541A (zh) * | 2012-10-31 | 2013-04-17 | 中国人民解放军第三军医大学 | 杂交瘤细胞株及其产生的抗人心脏型脂肪酸结合蛋白的单克隆抗体 |
CN103901216A (zh) * | 2014-04-22 | 2014-07-02 | 上海科华生物工程股份有限公司 | 人h-fabp胶体金检测试纸及其制备方法 |
WO2015142305A1 (en) * | 2014-03-20 | 2015-09-24 | S.K Teknoloji Arastirma Gelistirme San. Ve Tic. Ltd. Sti. | Monoclonal antibodies developed against h-fabp and the use thereof |
CN107119023A (zh) * | 2016-12-27 | 2017-09-01 | 南京诺唯赞医疗科技有限公司 | 耐脂肪酸干扰的抗人心型脂肪酸结合蛋白的单克隆抗体及其应用 |
CN111505303A (zh) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | 化学发光法检测心型脂肪酸结合蛋白试剂盒及使用方法 |
WO2024000345A1 (zh) * | 2022-06-30 | 2024-01-04 | 中国科学院深圳先进技术研究院 | 一种a-fabp单克隆抗体2c6及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1396453A (zh) * | 2002-05-17 | 2003-02-12 | 胡美浩 | 急性心肌梗塞早期诊断试剂盒 |
CN102226811A (zh) * | 2011-04-02 | 2011-10-26 | 吉林雅强医疗器械有限公司 | 一种检测尿液中心脏型脂肪酸结合蛋白诊断试纸的制备方法 |
-
2011
- 2011-10-28 CN CN201110336190A patent/CN102399752B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1396453A (zh) * | 2002-05-17 | 2003-02-12 | 胡美浩 | 急性心肌梗塞早期诊断试剂盒 |
CN102226811A (zh) * | 2011-04-02 | 2011-10-26 | 吉林雅强医疗器械有限公司 | 一种检测尿液中心脏型脂肪酸结合蛋白诊断试纸的制备方法 |
Non-Patent Citations (2)
Title |
---|
季鹏等: "人心脏型脂肪酸结合蛋白的纯化与鉴定", 《中国组织工程研究与临床康复》 * |
许淑芬等: "人H-FABP单克隆抗体制备和纯化及其特性鉴定", 《中国实验诊断学》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102735849A (zh) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | 一种人心肌脂肪酸结合蛋白酶促化学发光免疫检测方法和试剂盒 |
CN103045541A (zh) * | 2012-10-31 | 2013-04-17 | 中国人民解放军第三军医大学 | 杂交瘤细胞株及其产生的抗人心脏型脂肪酸结合蛋白的单克隆抗体 |
WO2015142305A1 (en) * | 2014-03-20 | 2015-09-24 | S.K Teknoloji Arastirma Gelistirme San. Ve Tic. Ltd. Sti. | Monoclonal antibodies developed against h-fabp and the use thereof |
CN103901216A (zh) * | 2014-04-22 | 2014-07-02 | 上海科华生物工程股份有限公司 | 人h-fabp胶体金检测试纸及其制备方法 |
CN103901216B (zh) * | 2014-04-22 | 2015-10-21 | 上海科华生物工程股份有限公司 | 人h-fabp胶体金检测试纸及其制备方法 |
CN107119023A (zh) * | 2016-12-27 | 2017-09-01 | 南京诺唯赞医疗科技有限公司 | 耐脂肪酸干扰的抗人心型脂肪酸结合蛋白的单克隆抗体及其应用 |
CN107119023B (zh) * | 2016-12-27 | 2018-01-12 | 南京诺唯赞医疗科技有限公司 | 耐脂肪酸干扰的抗人心型脂肪酸结合蛋白的单克隆抗体及其应用 |
CN111505303A (zh) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | 化学发光法检测心型脂肪酸结合蛋白试剂盒及使用方法 |
WO2024000345A1 (zh) * | 2022-06-30 | 2024-01-04 | 中国科学院深圳先进技术研究院 | 一种a-fabp单克隆抗体2c6及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102399752B (zh) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102399752B (zh) | 心脏型脂肪酸结合蛋白单克隆抗体mcf1及其应用 | |
CN101806804B (zh) | 用于免疫学方法检测急性心肌梗塞的试剂及测试条 | |
Ahle et al. | Structural relationships between clathrin assembly proteins from the Golgi and the plasma membrane. | |
CN101988924A (zh) | 检测血液抗环瓜氨酸多肽抗体的试纸条及制备方法 | |
CN102830229B (zh) | 梅毒螺旋体IgM抗体胶体金法检测试剂及其制备方法 | |
KR101520084B1 (ko) | 뎅기열 바이러스의 표피단백질 도메인1에 특이적인 단클론 항체를 포함하는 뎅기열 바이러스 항체의 신속진단키트 및 그 제조 방법 | |
CN102174474B (zh) | 西地那非单克隆抗体及用于检测西地那非的胶体金层析试纸条 | |
CN111518176B (zh) | 一种用于新型冠状病毒抗体双抗原夹心检测的配对抗原、检测试纸及其制备方法 | |
CN102030824A (zh) | 一种乙型肝炎病毒x蛋白单克隆抗体及用途 | |
CN109187986A (zh) | 一种便携式检测人抗甲状腺球蛋白抗体的试纸条及其制备方法 | |
CN103336132A (zh) | 一种检测泪液中乳铁蛋白的方法及其专用胶体金检测卡 | |
CN101580544A (zh) | 胶体金标记大麻、四氢大麻酚单抗免疫检测板 | |
CN103045541A (zh) | 杂交瘤细胞株及其产生的抗人心脏型脂肪酸结合蛋白的单克隆抗体 | |
CN103509760B (zh) | 可分泌抗β2-微球蛋白单克隆抗体的杂交瘤细胞及应用 | |
CN106699884B (zh) | 抗人c-反应蛋白抗体及其应用 | |
CN103149361A (zh) | 犬早孕因子胶体金检测试纸卡及其制备方法和应用 | |
CN112142833B (zh) | 一种呋塞米人工抗原、抗体及其在检测呋塞米中的应用 | |
CN102358895A (zh) | 一种单克隆抗体mcf2及其应用 | |
CN105399639A (zh) | 一种酪胺人工抗原和抗体及其制备方法与应用 | |
CN106093431B (zh) | 人降钙素原胶体金定量检测卡 | |
CN102336814A (zh) | 一种用于制备抗肝脏肿瘤标志物ck-19抗体的多肽序列、多克隆抗体与应用 | |
CN104142400A (zh) | 一种基于检测循环抗原的诊断黑热病的免疫层析试条 | |
CN105296520A (zh) | 一种人肿瘤抗原3H11Ag的制备方法及其酶联免疫检测试剂盒 | |
CN101497663A (zh) | 用于检测和测定黄芩苷的抗体、方法和试剂盒 | |
CN101392022B (zh) | 葎草花粉主要致敏蛋白单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: NO.1 ATTACHED HOSPITAL, NANJING MEDICAL UNIV. Effective date: 20120503 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120503 Address after: 210029 Nanjing, Gulou District, Jiangsu, No. 300 Guangzhou Road Applicant after: Yang Di Address before: 210029 Nanjing, Gulou District, Jiangsu, No. 300 Guangzhou Road Applicant before: THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 |
|
CF01 | Termination of patent right due to non-payment of annual fee |